SepsisAdrenomed set to start pivotal trial in se...German Adrenomed AG has got a recommendation from the EMA to push its Adrenomedullin-binding antibody Adrecizumab into a pivotal Phase III study. more ➔
financingMablink raises $31m in Series A financingMablink Bioscience has baged €31m in a Series A round led by Sofinnova Partners and Mérieux Equity Partners to speed up its pipeline of ADCs. more ➔
Industria Experts showcase next-gen biotech solution...Industry experts have presented the latest biotech solutions for tackling climate change at the first INDUSTRIA BIOTEC conference, Europe’s new forum for the industrial biotech sector. more ➔
partnerStalicla SA and Evgen Pharma plc ink $160....Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. more ➔
Clinical Microbiomics A/S bags €10m fina...Danish microbiome specialist Clinical Microbiomics A/S has completed a €10m growth financing led by – Seventure Partners. more ➔
EU starts largest study on factors affecti...The EU Commission has granted £8.4m for Youth-GEMS, the largest ever study to identify genetic and other risks affecting mental health in adolescence. more ➔
Standing Ovation wins Industria BiotecR...French Standing Ovation has won the start-up pitch of Industria Biotec, held for the first time in Berlin. The event presents biotechnological solutions to save the climate. more ➔
financingAraris Biotech closes $24m Series A financ...Swiss ADC maker Araris Biotech AG has added a $24m financing round to its CHF15.2m (S17.8m) seed round in 2020 to expand its portfolio of proprietary antibody drug conjugates. more ➔
FundingNew Protein Fund I supports 17 alternative...With money from its $50m New Protein Fund, Big Idea Ventures funds in 17 pre-seed plant-based, cell-based and microbial food, ingredient and technology companies. more ➔
Sibylla Biotech raises €23m Series AVerona-based Sibylla Biotech has closed a €23m Series A financing round to advance its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) platform. more ➔
